As Wall Street becomes gripped by the drama of Valeant — the drug company that has been under assault from both short sellers and Washington's war on drug prices — Jim Cramer would like to finally acknowledge that not every drug company roll-up is like Valeant.
Horizon Pharma is a $3.5 billion roll-up company. Roll-ups gain most of their growth through making a series of acquisitions. And while the company only has a market cap of $3.5 billion, significantly smaller than Valeant, its stock has been trading like a miniature version of Valeant.
Read MoreClick here to watch the full "Mad Money" interview
When Horizon Pharma reported on Friday, it blew away the numbers. The company has seven drugs on the market that target unmet needs in pain, rheumatology and rare orphan diseases. It reported a stellar 34-cent earnings beat from a 40-cent basis, and management provided spectacular full-year guidance.